Weight loss, induced by increased energy expenditure and reduced energy intake, occurs regularly during prolonged exposure to altitude above 5000 m. Loss of fat accounts for up to 74% of this weight loss. 1 Furthermore, loss of appetite is one of the most frequent symptoms of acute mountain sickness (AMS).
Weight loss, induced by increased energy expenditure and reduced energy intake, occurs regularly during prolonged exposure to altitude above 5000 m. Loss of fat accounts for up to 74% of this weight loss. 1 Furthermore, loss of appetite is one of the most frequent symptoms of acute mountain sickness (AMS). 2 As leptin is a key mediator in the neuroendocrine regulation of energy homeostasis and appetite, 3 we investigated the effect of hypobaric hypoxia at high altitude on serum leptin levels in men, using a highly sensitive and speci®c method for leptin quanti®cation. 4 Mean serum leptin levels in 20 male mountaineers after active ascent to 4559 m (age: 19 ± 42 y) increased from 1.22 AE 0.19 ngaml (120 m, all values mean AE s.e.m. 9:00 a.m.) to 2.06 AE 0.34 ngaml (mean pO 2 : 43.2 mmHg, 9:00 a.m., 22 h after ascent, P 0.0003). This effect was not reversible after 1 h of treatment with 33% oxygenenriched air and appeared to be more pronounced in subjects with loss of appetite (78% increase, n 11), than in those without loss of appetite (52% increase, n 9). Loss of appetite was documented by the Environmental Symptom Questionnaire. 1 However, physical strain during the active ascent and single measurements of leptin, which is secreted in a pulsatile manner by adipocytes were identi®ed as possible confounding factors in this study. Therefore, in a second study serum leptin levels were measured in 18 volunteers (age: 20 ± 41 y) at 490 m (after 1, 4, 12 and 20 h) and at 4559 m (1, 4, 12, 20 (and 32) h after transportation by helicopter). In individuals with loss of appetite mean serum leptin levels increased from 3.19 AE 0.89 ngaml (490 m, 6:00 a.m.) to 4.89 AE 1.18 ngaml (4559 m, 6:00 a.m., P 0.02, n 12), but no signi®cant increase was found in individuals without loss of appetite (2.17 ngaml vs 2.55 ngaml, n 6, 6:00 a.m., P 0.35). An increase in integrated serum leptin levels (mean area under the curve) from 53.8 AE 13.8 ngaml h to 66.3 AE 16.2 ngaml h was found in individuals with loss of appetite (1 ± 20 h, P 0.008), but not in volunteers without loss of appetite (38.7 AE 6.4 ngaml h (490 m), 6.00 a.m. 40.8AE 13.2 ngaml h (4559 m, P 0.35). As loss of appetite is a frequent symptom of AMS 2 it is not surprising that at 4559 m a signi®cant increase in serum leptin levels was also found in those volunteers with AMS, compared to levels at 490 m. AMS was de®ned as a functional Lake Louise Score b1 (n 10, P 0.028). 5 Statistics were performed by non-parametric testing (Mann ± Whitney test and Wilcoxon test). Effects due to change in plasma volume have been excluded. Individuals with loss of appetite showed a tendency to higher leptin levels baseline than those without loss of appetite (P 0.1), but mean body mass indices were not signi®cantly different between the analysed subgroups. In summary, in two independent studies, elevated leptin levels at high altitude were demonstrated, and found to be associated with loss of appetite. Thus, leptin may be a player in the altered neuroendocrine regulation of energy homeostasis at high altitude, leading to loss of appetite, increased energy expenditure and weight loss.
